F. Gamza
8 works · 1,434 citations · h-index 4
Top works
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)
- Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study
- 427 POSTER Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study
- 398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours
- Randomized P hase I II T rial o f D ocetaxel V ersus Vinorelbine o r I fosfamide i n P atients W ith A dvanced N on- Small-Cell L ung C ancer P reviously T reated W ith P latinum- Containing C hemotherapy R egimens
- Prognostic factors for safety in non small cell lung cancer patients treated with Taxotere®. A multivariate analysis
- Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based chemotherapy